Robert W Robey

List of Publications by Year
in descending order

113 papers	10,564 citations	34105 52 h-index	31849 101 g-index
120 all docs	120 docs citations	120 times ranked	10857 citing authors

#	Article	IF	Citations
1	A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chemico-Biological Interactions, 2022, 351, 109718.	4.0	4
2	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643.	3.7	2
3	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. Translational Oncology, 2021, 14, 100917.	3.7	8
4	ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model. , 2021, 4, 620-633.		3
5	R-Loopâ€“Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin. Molecular Cancer Research, 2021, 19, 1361-1374.	3.4	12
6	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature Communications, 2021, 12, 2804.	12.8	77
7	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
8	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter. Scientific Reports, 2021, 11, 24150.	3.3	15
9	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. Journal of Medicinal Chemistry, 2020, 63, 1434-1439.	6.4	4
10	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3794.	4.1	14
11	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. Experimental Cell Research, 2020, 388, 111860.	2.6	26
12	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000Research, 2020, 9, 17.	1.6	25
13	Model systems for studying the blood-brain barrier: Applications and challenges. Biomaterials, 2019, 214, 119217.	11.4	50
14	Spatial control of oxygen delivery to threeâ€dimensional cultures alters cancer cell growth and gene expression. Journal of Cellular Physiology, 2019, 234, 20608-20622.	4.1	17
15	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. Cancer Letters, 2019, 457, 110-118.	7.2	39
16	Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. Drug Metabolism and Disposition, 2019, 47, 715-723.	3.3	17
17	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology, 2019, 96, 629-640.	2.3	22
18	Inside Cover Image, Volume 234, Number 11, November 2019. Journal of Cellular Physiology, 2019, 234, ii.	4.1	0

#	Article	IF	Citations
19	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. Experimental Cell Research, 2019, 375, 106-112.	2.6	15
20	Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018, 18, 452-464.	28.4	1,181
21	Bax/Tubulin/Epithelial-Mesenchymal Pathways Determine the Efficacy of Silybin Analog HM015k in Colorectal Cancer Cell Growth and Metastasis. Frontiers in Pharmacology, 2018, 9, 520.	3.5	12
22	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	7.0	38
23	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
24	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget, 2016, 7, 69804-69815.	1.8	14
25	CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio. Clinical Cancer Research, 2015, 21, 2195-2197.	7.0	6
26	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. International Journal of Biochemistry and Cell Biology, 2014, 51, 111-119.	2.8	29
27	Histone deacetylase inhibitorâ€mediated cell death is distinct from its global effect on chromatin. Molecular Oncology, 2014, 8, 1379-1392.	4.6	39
28	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	1.8	41
29	Assessment of Drug Transporter Function Using Fluorescent Cell Imaging. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2013, 57, Unit 23.6..	1.1	19
30	Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2. Drug Metabolism and Disposition, 2013, 41, 1805-1812.	3.3	42
31	Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biology and Therapy, 2013, 14, 175-183.	3.4	15
32	Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle, 2013, 12, 2829-2838.	2.6	24
33	MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood, 2013, 121, 4115-4125.	1.4	69
34	Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle, 2012, 11, 963-973.	2.6	13
35	A Pharmacodynamic Study of the Pâ€glycoprotein Antagonist CBTâ€1Â® in Combination With Paclitaxel in Solid Tumors. Oncologist, 2012, 17, 512.	3.7	37
36	Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter. Cancer Research, 2012, 72, 3642-3651.	0.9	42

#	Article	IF	Citations
37	HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1. Cancer Research, 2012, 72, 4204-4213.	0.9	12
38	Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e45268.	2.5	27
39	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research, 2011, 17, 569-580.	7.0	149
40	Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. Molecular Pharmaceutics, 2011, 8, 2021-2031.	4.6	110
41	The Challenge of Exploiting ABCG2 in the Clinic. Current Pharmaceutical Biotechnology, 2011, 12, 595-608.	1.6	66
42	The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry, 2011, 50, 209-232.	4.7	185
43	Rapid detection of ABC transporter interaction: Potential utility in pharmacology. Journal of Pharmacological and Toxicological Methods, 2011, 63, 217-222.	0.7	34
44	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.9	157
45	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral Tâ€cell lymphoma. British Journal of Haematology, 2010, 148, 256-267.	2.5	74
46	Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Drug Metabolism and Disposition, 2010, 38, 1371-1380.	3.3	202
47	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy, 2010, 10, 997-1008.	2.4	215
48	ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 625-633.	1.7	82
49	Mutational Analysis of Threonine 402 Adjacent to the GXXXG Dimerization Motif in Transmembrane Segment 1 of ABCG2. Biochemistry, 2010, 49, 2235-2245.	2.5	38
50	Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 2009, 37, 359-365.	3.3	209
51	Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Molecular Cancer Therapeutics, 2009, 8, 2959-2968.	4.1	107
52	A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research, 2009, 15, 3574-3582.	7.0	101
53	Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen. Molecular Pharmacology, 2009, 76, 946-956.	2.3	26
54	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochemical Pharmacology, 2009, 77, 781-793.	4.4	69

#	Article	IF	Citations
55	The 315â€“316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. Molecular and Cellular Biochemistry, 2009, 322, 63-71.	3.1	4
56	Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemotherapy and Pharmacology, 2009, 64, 575-583.	2.3	25
57	ABCG2: A perspective. Advanced Drug Delivery Reviews, 2009, 61, 3-13.	13.7	409
58	Botryllamides: Natural Product Inhibitors of ABCG2. ACS Chemical Biology, 2009, 4, 637-647.	3.4	49
59	Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1434-1443.	2.6	26
60	ABCG2 is expressed in late spermatogenesis and is associated with the acrosome. Biochemical and Biophysical Research Communications, 2009, 378, 302-307.	2.1	14
61	Multidrug Resistance Mediated by MDR-ABC Transporters. , 2009, , 1-20.		5
62	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncology Reports, 2009, 21, 483-9.	2.6	42
63	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU International, 2008, 102, 1694-1699.	2.5	22
64	Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1Â®. Biochemical Pharmacology, 2008, 75, 1302-1312.	4.4	143
65	ABCG2: structure, function and role in drug response. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1-15.	3.3	182
66	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.9	362
67	P-Glycoproteinâ€”a Clinical Target in Drug-Refractory Epilepsy?. Molecular Pharmacology, 2008, 73, 1343-1346.	2.3	54
68	Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle, 2008, 7, 940-949.	2.6	91
69	Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan. Molecular Pharmacology, 2008, 73, 490-497.	2.3	36
70	Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Molecular Cancer Therapeutics, 2007, 6, 1877-1885.	4.1	57
71	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biology and Therapy, 2007, 6, 432-438.	3.4	177
72	Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone. Clinical Cancer Research, 2007, 13, 7480-7486.	7.0	24

#	Article	IF	Citations
73	New inhibitors of ABCG2 identified by high-throughput screening. Molecular Cancer Therapeutics, 2007, 6, 3271-3278.	4.1	57
74	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.9	280
75	Side Population Analysis Using a Violet-Excited Cell-Permeable DNA Binding Dye. Stem Cells, 2007, 25, 1029-1036.	3.2	101
76	ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews, 2007, 26, 39-57.	5.9	350
77	The Calcium Channel Blockers, 1,4-Dihydropyridines, Are Substrates of the Multidrug Resistance-Linked ABC Drug Transporter, ABCG2. Biochemistry, 2006, 45, 8940-8951.	2.5	91
78	Mutational Studies of G553 in TM5 of ABCG2:Â A Residue Potentially Involved in Dimerizationâ€. Biochemistry, 2006, 45, 5251-5260.	2.5	36
79	The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. Research in Veterinary Science, 2006, 81, 345-349.	1.9	20
80	Characterization of Gene Rearrangements Leading to Activation of MDR-1*. Journal of Biological Chemistry, 2006, 281, 36501-36509.	3.4	48
81	A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity. Journal of Biomolecular Screening, 2006, 11, 176-183.	2.6	128
82	A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Molecular Cancer Therapeutics, 2006, 5, 450-456.	4.1	33
83	Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research, 2006, 12, 1547-1555.	7.0	97
84	New and Revised Concepts in Multidrug Resistance. , 2006, , 261-282.		1
85	Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. Cancer Genetics and Cytogenetics, 2005, 160, 126-133.	1.0	31
86	Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemotherapy and Pharmacology, 2005, 56, 161-172.	2.3	217
87	ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates. Cancer Research, 2005, 65, 8414-8422.	0.9	57
88	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. Clinical Cancer Research, 2005, 11, 8503-8511.	7.0	10
89	Inhibitors of Histone Deacetylases Alter Kinetochore Assembly by Disrupting Pericentromeric Heterochromatin. Cell Cycle, 2005, 4, 717-726.	2.6	105
90	ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biology and Therapy, 2005, 4, 195-202.	3.4	175

#	Article	IF	Citations
91	ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biology and Therapy, 2005, 4, 187-94.	3.4	65
92	ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 836-842.	2.5	81
93	A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 4724-4733.	7.0	69
94	Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition. Cancer Research, 2004, 64, 1242-1246.	0.9	331
95	Mutational Analysis of ABCG2:â€‰ Role of the GXXXG Motif. Biochemistry, 2004, 43, 9448-9456.	2.5	96
96	T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 2004, 103, 4636-4643.	1.4	188
97	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Research, 2003, 63, 4048-54.	0.9	245
98	Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biology and Therapy, 2002, 1, 696-702.	3.4	109
99	Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood, 2002, 99, 2248-2251.	1.4	34
100	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer, 2002, 94, 2333-2343.	4.1	119
101	Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry, 2002, 48, 59-65.	1.8	75
102	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer, 2002, 94, 2333-2343.	4.1	1
103	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 2002, 8, 718-28.	7.0	410
104	Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Research, 2002, 62, 5035-40.	0.9	188
105	A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochimica Et Biophysica Acta - Biomembranes, 2001, 1512, 171-182.	2.6	216
106	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 2001, 98, 2865-2868.	1.4	458
107	Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. Journal of Clinical Oncology, 2001, 19, 832-842.	1.6	95
108	Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism 1 1Abbreviations: MTs, microtubules; MAPs, microtubule-associated proteins; MAP4, microtubule-associated protein-4; PTX, paclitaxel; EPOA, epothilone A; EPOB, epothilone B; EPOA-R, epothilone A-resistant; COL, colchicine; VCR, vincristine; and VBL, vinblastine.. Biochemical Pharmacology, 2001, 62, 1469-1480.	4.4	53

#	Article	IF	Citations
109	Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na⁺/I^{â^'}Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3430-3435.	3.6	144
110	FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-Cancer Drugs, 2000, 11, 445-454.	1.4	35
111	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. Journal of Cellular Biochemistry, 1997, 65, 513-526.	2.6	87
112	Clinical Reversal of Multidrug Resistance. Stem Cells, 1996, 14, 56-63.	3.2	31
113	Clinical Reversal of Multidrug Resistance. Oncologist, 1996, 1, 269-275.	3.7	5